Medsider: Learn from MedTech and HealthTech Experts

How Medtech Companies Should Approach the Consumer Health Market: Interview with Movano CEO John Mastrototaro

May 25, 2022 Scott Nelson
Medsider: Learn from MedTech and HealthTech Experts
How Medtech Companies Should Approach the Consumer Health Market: Interview with Movano CEO John Mastrototaro
Show Notes

In this episode of Medsider Radio, we sat down with John Mastrototaro, CEO of Movano.

John has more than 30 years’ worth of experience in the medical device industry and was part of the MiniMed team that helped develop the world’s first ambulatory continuous glucose monitoring system and sensor-augmented insulin pump. John is now CEO and Director of Movano, a health technology company that makes smart, personalized devices that can provide vital health information to users. 

In this conversation, we discuss how medtech companies can build a successful consumer-facing brand while developing products that meet the needs of payers and providers.  

Before we jump into the discussion, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with John if you'd rather read it instead.